Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Galderma R&D122 enrolled

Overview

Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

Same as above.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

122

Conditions

Plaque Psoriasis

Interventions

Clobetasol Propionate, 0.05%DRUG

Topical, twice daily for 4 weeks

Calcipotriene and betamethasone dipropionate ointmentDRUG

Topical, once daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Moderate to severe psoriasis involving 3-20% of the body surface area Exclusion Criteria: * Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment * Subjects having psoriasis that involves the scalp, face, or groin

Locations (4)

Minnesota Clinical Study Center

Fridley, Minnesota, United States

DermResearch, Inc.

Austin, Texas, United States

J & S Studies, Inc.

Bryan, Texas, United States

Baylor Research Institute

Dallas, Texas, United States

Outcomes

Primary Outcomes

Overall Disease Severity

Time frame: End of treatment (Week 4)

Tolerability assessments, incidence of adverse events

Time frame: Baseline, Weeks 1, 2, 4 and 8

Secondary Outcomes

Overall Disease Severity

Time frame: Weeks 1, 2 and 8

Investigator Global Assessment

Time frame: End of treatment (week 4) and Weeks 1, 2 and 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.